Boston, MA
Summary
This biotechnology company focuses on curing blood cancers through innovative cell and genome engineering techniques. Their unique approach involves developing shielded transplants that allow for the delivery of potentially curative treatments after a stem cell transplant, specifically targeting acute myeloid leukemia (AML) and other blood cancers. The company utilizes a proprietary platform that integrates Hematopoietic Stem Cell (HSC) biology, genome engineering, and CAR-T cell technology to enhance treatment efficacy and reduce relapse rates.
Based on content on vorbio.com
No similar companies found
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
12.4 years — Since Aug 2012
Web Hosting
Platform
E-Mail Provider
Mimecast
NAICS Code
541714
SIC 4 Digit Code
8731
SIC 2 Digit Code
87
Industry
1. Biotechnology
2. Research and Development in Biotechnology (except Nanobiotechnology)
Vendor
Source
Apple
TXT Record
Atlassian
TXT Record
DocuSign
TXT Record
KnownBe4
TXT Record
Smartsheet
TXT Record
Salesforce
TXT Record
Mimecast
TXT Record
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2012 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2013 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2014 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 |
|
|
|
|
|
|
|
|
|
|
|
|